Targeting Candida albicans filamentation for antifungal drug development.
Candida albicans remains the main etiological agent of candidiasis, as this otherwise normal commensal of humans is capable of causing active infection in immune- and medically-compromised patients. The high morbidity and mortality rates associated with candidiasis, coupled with the emergence of drug resistance demand the development of novel therapeutic strategies. However, there is a paucity of selective targets that can be exploited in the development of new antifungals. Contrary to conventional antibiotics that kill or curtail growth, specifically targeting virulence mechanisms represents an attractive option for antifungal drug development. In C. albicans, a growing body of research over the last few decades has provided important insights into its virulence factors and their contribution to the pathogenesis of candidiasis. Of these, filamentation is the one that has received the most attention and perhaps shows the most promise as a target for new anti-virulence strategies to combat C. albicans infections.
['Vila|Taissa|T|', 'Romo|Jesus A|JA|', 'Pierce|Christopher G|CG|', 'McHardy|Stanton F|SF|', 'Saville|Stephen P|SP|', 'Lopez-Ribot|José L|JL|']
D000935:Antifungal Agents D002176:Candida albicans D002177:Candidiasis D055808:Drug Discovery D006801:Humans D025301:Hyphae D015398:Signal Transduction D014774:Virulence D037521:Virulence Factors
Candida albicans filamentation candidiasis anti-virulence therapeutics